摘要
Background: In the phase 3 CheckMate 078 study, nivolumab showed significant overall survival (OS) benefit and superior tolerability versus docetaxel in a predominantly Chinese patient population with non-small cell lung cancer (NSCLC). However, data on long-term outcomes with immunotherapy in Asian patients are limited. We report 2-year efficacy and safety data. @@@ Methods: Patients with advanced/metastatic NSCLC and disease progression after platinum-doublet chemotherapy were randomized 2:1 to nivolumab (3 mg/kg every 2 weeks; n = 338) or docetaxel (75 mg/m(2) every 3 weeks; n = 166) until progression, unacceptable toxicity, or other protocol-defined reasons. The primary endpoint was OS; secondary endpoints included progression-free survival, objective response rate, and safety. @@@ Results: After 25.9 months minimum follow-up, 21 patients (6 %) remained on nivolumab versus 0 on docetaxel. Median OS was 11.9 months with nivolumab versus 9.5 months with docetaxel (HR: 0.75; 95 % CI: 0.61-0.93); 2 year OS rates were 28 % versus 18 %, respectively. Survival benefits were observed across a variety of predefined subgroups. At 2 years, 39 % and 0 % of responders had ongoing responses with nivolumab and docetaxel, respectively. Grade 3-4 treatment-related adverse events occurred in 12 % of patients with nivolumab versus 47 % with docetaxel, leading to discontinuation in 4 % and 5 % of patients, respectively. No new treatment-related deaths occurred. @@@ Conclusion: At 2 years, nivolumab maintained a favorable safety profile and continued to demonstrate superior OS versus docetaxel in this predominantly Chinese patient population with previously treated NSCLC. These data are consistent with long-term outcomes from the global CheckMate 017/057 studies.
学科与关键词
- Three-year follow-up and patient-reported outcomes from CheckMate 078: Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancerChang, Jianhua; Wu, Yi-Long; Lu, Shun; Wang, Jie; Mok, Tony; Zhang, Li; Feng, Jifeng; Wu, Lin; Tu, Hai-Yan; Zhang, Yiping; Luft, Alexander; Zhou, Jian-ying; Ma, Zhiyong; Lu, You; Hu, Chengping; Shi, Yuankai; Poddubskaya, Elena; Soo, Ross A.; Chia, Yee Hong; Penrod, John R.; Taylor, Fiona; Lawrance, Rachael; Blum, Steven, I; Sun, Xiaowu; Juarez-Garcia, Ariadna; Moreno-Koehler, Alejandro; Li, Ang; Li, Amy; Cheng, Ying*Lung Cancer, 2022, 165: 71-81.被引 8
- An open label, safety study of Asian patients with advanced non-small-cell lung cancer receiving second-line nivolumab monotherapy (CheckMate 870)Lu, Shun*; Cheng, Ying; Zhou, Jianying; Wang, Mengzhao; Zhao, Jun; Wang, Baocheng; Chen, Gongyan; Feng, Jifeng; Ma, Zhiyong; Wu, Lin; Wang, Changli; Ma, Kewei; Zhang, Shucai; Liang, Jun; Song, Yong; Wang, Jie; Wu, Yi-Long; Li, Ang; Huang, Yizhi; Chang, JianhuaTherapeutic Advances in Medical Oncology, 2022, 14.被引 2
- Flat-dose nivolumab (NIVO) as second-line (2L) treatment (tx) in Asian patients (pts) with advanced non-small cell lung cancer (NSCLC): CheckMate 870 long-term resultsLu, S.; Cheng, Y.; Zhou, J.; Wang, M.; Zhao, J.; Wang, B.; Chen, G.; Feng, J.; Ma, Z.; Wu, L.; Wang, C.; Ma, K.; Zhang, S.; Liang, J.; Song, Y.; Wang, J.; Wu, Y-L.; Li, A.; Huang, Y.; Chang, J.European Lung Cancer Congress (ELCC), ELECTR NETWORK, 2022-03-30 To 2022.
